Breaking News Instant updates and real-time market news.

CBAY

CymaBay

17:49
09/19/17
09/19
17:49
09/19/17
17:49

CymaBay initiated with an Overweight at Cantor

Cantor Fitzgerald analyst William Tanner started CymaBay Therapeutics with an Overweight rating and $16 price target. The analyst believes the company's seladelpar could become an important new therapy for primary biliary cholangitis and a possible treatment for non-alcoholic steatohepatitis.

  • 25

    Sep

  • 27

    Sep

CBAY CymaBay

09/14/17
OPCO
09/14/17
NO CHANGE
Target $15
OPCO
Outperform
Intercept Ocaliva dynamics highlight PBC opportunity, says Oppenheimer
Oppenheimer analyst Jay Olson says the Dear Doctor letter for Intercept's (ICPT) Ocaliva raises awareness of unmet medical need for patients with primary biliary cholangitis, or PBC. Since patients with Child-Pugh B/C cirrhosis were not studied in Ocaliva trials, the analyst believes the FDA's collaboration with Intercept to leverage PK modeling for dosing guidance which is included in the label and emphasized in the Dear Doctor letter highlights the importance of providing novel treatments to PBC patients. Olson expects these events to have a positive impact on the treatment of all PBC patients, and says CymaBay (CBAY) may benefit from these dynamics. He reiterates an Outperform rating and $15 price target on CymaBay's shares.
08/23/17
LEER
08/23/17
INITIATION
Target $12
LEER
Outperform
CymaBay initiated with an Outperform at Leerink
Leerink analyst Joseph Schwartz started CymaBay with an Outperform rating and $12 price target, noting that the company is currently developing seladelpar for the lead indication of primary biliary cholangitis, an autoimmune disease that causes progressive destruction of the bile ducts in the liver.
08/18/17
RHCO
08/18/17
INITIATION
RHCO
Buy
CymaBay initiated with a Buy at SunTrust
SunTrust analyst Edward Nash started coverage of CymaBay with a $15 price target and a Buy rating. He is upbeat on the outlook for the company's seladelpar, a treatment for a rare liver disease called primary biliary cholangitis. According to the analyst ,the drug has "well defined approvable endpoints and a primed commercial opportunity,"
08/11/17
IFSG
08/11/17
DOWNGRADE
Target $13
IFSG
Outperform
CymaBay downgraded to Outperform from Strong Buy at IFS Securities
IFS Securities analyst David Bouchey downgraded CymaBay to Outperform from Strong Buy, saying he sees now as a good time to step back with additional news flow not expected to pick until 2018. He lowered his price target on CymaBay to $13 from $18.

TODAY'S FREE FLY STORIES

NAVI

Navient

$12.20

0.47 (4.01%)

07:17
10/18/17
10/18
07:17
10/18/17
07:17
Hot Stocks
Navient sees adding over $1B of education refinance loans in FY17 »

Including the planned…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

07:16
10/18/17
10/18
07:16
10/18/17
07:16
Conference/Events
Commodity Futures Trading Commission Commissioners to speak at Expo »

Brian Quintenz and Rostin…

FGEN

FibroGen

$55.30

0.8 (1.47%)

, AZN

AstraZeneca

$34.78

0.13 (0.38%)

07:16
10/18/17
10/18
07:16
10/18/17
07:16
Hot Stocks
FibroGen announces CFDA acceptance of roxadustat NDA »

FibroGen (FGEN) and its…

FGEN

FibroGen

$55.30

0.8 (1.47%)

AZN

AstraZeneca

$34.78

0.13 (0.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 08

    Nov

  • 09

    Nov

CMG

Chipotle

$329.30

8.91 (2.78%)

07:16
10/18/17
10/18
07:16
10/18/17
07:16
Technical Analysis
Technical View: Chipotle falls, analyst actions »

The shares were last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

UNH

UnitedHealth

$203.89

10.69 (5.53%)

, AMZN

Amazon.com

$1,009.13

2.79 (0.28%)

07:16
10/18/17
10/18
07:16
10/18/17
07:16
Recommendations
UnitedHealth, Amazon.com analyst commentary  »

UnitedHealth price target…

UNH

UnitedHealth

$203.89

10.69 (5.53%)

AMZN

Amazon.com

$1,009.13

2.79 (0.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 22

    Oct

  • 26

    Oct

  • 18

    Mar

AAN

Aaron's

$41.55

0.01 (0.02%)

07:15
10/18/17
10/18
07:15
10/18/17
07:15
Initiation
Aaron's initiated  »

Aaron's initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

BMTC

Bryn Mawr Bank

$44.50

-0.1 (-0.22%)

, FCF

First Commonwealth

$13.94

-0.26 (-1.83%)

07:13
10/18/17
10/18
07:13
10/18/17
07:13
Conference/Events
FDIC to hold a committee meeting »

The FDIC's Advisory…

BMTC

Bryn Mawr Bank

$44.50

-0.1 (-0.22%)

FCF

First Commonwealth

$13.94

-0.26 (-1.83%)

ONB

Old National Bancorp

$18.40

-0.05 (-0.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 24

    Oct

  • 25

    Oct

  • 06

    Nov

HCC

Warrior Met Coal

$24.04

0.51 (2.17%)

07:13
10/18/17
10/18
07:13
10/18/17
07:13
Downgrade
Warrior Met Coal rating change  »

Warrior Met Coal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MOH

Molina Healthcare

$61.54

1.68 (2.81%)

, UNH

UnitedHealth

$203.89

10.69 (5.53%)

07:13
10/18/17
10/18
07:13
10/18/17
07:13
Periodicals
Health insurers prepare for enrollment drop amid ACA uncertainty, WSJ says »

As enrollment for 2018…

MOH

Molina Healthcare

$61.54

1.68 (2.81%)

UNH

UnitedHealth

$203.89

10.69 (5.53%)

CNC

Centene

$93.80

2.88 (3.17%)

WCG

WellCare

$174.03

6.11 (3.64%)

CI

Cigna

$187.20

2.21 (1.19%)

ANTM

Anthem

$187.26

3.5 (1.90%)

HNT

Health Net

HUM

Humana

$240.43

3.26 (1.37%)

AET

Aetna

$155.90

4.46 (2.95%)

EHTH

eHealth

$23.79

-0.61 (-2.50%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 25

    Oct

  • 26

    Oct

  • 31

    Oct

  • 31

    Oct

  • 02

    Nov

  • 02

    Nov

  • 06

    Nov

  • 08

    Nov

  • 14

    Dec

IBM

IBM

$146.54

-0.29 (-0.20%)

07:12
10/18/17
10/18
07:12
10/18/17
07:12
Recommendations
IBM analyst commentary  »

IBM reported 'best…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 15

    Nov

NVO

Novo Nordisk

$49.31

-0.01 (-0.02%)

07:12
10/18/17
10/18
07:12
10/18/17
07:12
Conference/Events
FDA Endocrinologic & Metabolic Drugs Advisory Committee to hold a meeting »

The Committee discusses…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

TSLA

Tesla

$355.75

5.15 (1.47%)

07:11
10/18/17
10/18
07:11
10/18/17
07:11
Periodicals
Tesla employees claim dismissals not performance related, CNBC reports »

Tesla is trying to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

ATTU

Attunity

$6.90

0.12 (1.77%)

07:11
10/18/17
10/18
07:11
10/18/17
07:11
Hot Stocks
Attunity's Replicate adopted by large health insurance provider »

Attunity announced that a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Nov

MYGN

Myriad Genetics

$35.84

-0.26 (-0.72%)

07:10
10/18/17
10/18
07:10
10/18/17
07:10
Hot Stocks
Myriad Genetics BRACAnalysis CDx sPMA by FDA for review »

Myriad Genetics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Nov

MAIN

Main Street

$40.07

-0.1 (-0.25%)

07:09
10/18/17
10/18
07:09
10/18/17
07:09
Hot Stocks
Main Street announces semi-annual supplemental cash dividend of 27.5c per share »

Main Street Capital is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Nov

JNJ

Johnson & Johnson

$140.79

4.67 (3.43%)

07:09
10/18/17
10/18
07:09
10/18/17
07:09
Recommendations
Johnson & Johnson analyst commentary  »

Johnson & Johnson…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 27

    Oct

  • 06

    Nov

IONS

Ionis Pharmaceuticals

$63.85

2.7 (4.42%)

07:09
10/18/17
10/18
07:09
10/18/17
07:09
Hot Stocks
Ionis collaborates with Seventh Sense Biosystems in blood collection device »

Ionis Pharmaceuticals has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 26

    Oct

LRCX

Lam Research

$194.55

2.19 (1.14%)

07:08
10/18/17
10/18
07:08
10/18/17
07:08
Recommendations
Lam Research analyst commentary  »

Lam Research price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IMRN

Immuron

$5.03

0.1 (2.03%)

07:06
10/18/17
10/18
07:06
10/18/17
07:06
Initiation
Immuron initiated  »

Immuron initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLRX

BioLineRx

$1.09

-0.065 (-5.63%)

, RHHBY

Roche

$31.45

0.27 (0.87%)

07:05
10/18/17
10/18
07:05
10/18/17
07:05
Hot Stocks
BioLineRx: Genentech initiates Phase 1b/2 trial for BL-8040 »

BioLineRx (BLRX)…

BLRX

BioLineRx

$1.09

-0.065 (-5.63%)

RHHBY

Roche

$31.45

0.27 (0.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 06

    Nov

  • 30

    Nov

CEVA

CEVA

$45.40

0.1 (0.22%)

07:05
10/18/17
10/18
07:05
10/18/17
07:05
Hot Stocks
CEVA and Brodmann17 partner for deep learning in edge devices »

CEVA and Broadmann17, a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

LRCX

Lam Research

$194.55

2.19 (1.14%)

07:05
10/18/17
10/18
07:05
10/18/17
07:05
Recommendations
Lam Research analyst commentary  »

Lam Research price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TTOO

T2 Biosystems

$4.21

-0.05 (-1.17%)

07:05
10/18/17
10/18
07:05
10/18/17
07:05
Initiation
T2 Biosystems initiated  »

T2 Biosystems initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Nov

HNHPF

Hon Hai Precision

07:04
10/18/17
10/18
07:04
10/18/17
07:04
Periodicals
Foxconn, IDG Capital seek $1.5B for auto tech fund, Bloomberg reports »

Foxconn and IDG Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BRO

Brown & Brown

$49.01

0.04 (0.08%)

07:04
10/18/17
10/18
07:04
10/18/17
07:04
Hot Stocks
Brown & Brown announces asset acquisition of Lapeyre, Staples & Robichaux »

Brown & Brown and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.